pharma news today glp-1 obesity drug updates GLP-1s and the Unintended Consequences of the $100 Billion Market Market Overview: GLP-1 Agonists and

While telehealth expands access, it should not replace thorough monitoring

As GLP1RA medications continue to be hailed for their effectiveness in weight loss and diabetes management, these insights underline the importance of monitoring and addressing potential behavioural impacts

Intestinal dysbiosis, by increasing inflammation, can alter the tryptophan pathway with increased indoleamine 2,3-dioxygenase (IDO) activity that reduces the tryptophan metabolism to serotonin and increases the kinurenine pathway with overproduction of quinolinic acid (QA), which has inflammatory effects in the brain [105]

GLP-1 medicines like semaglutide and tirzepatide rarely list hair loss as a side effect